News
OCGN
--
0.00%
--
Ocugen To Participate In Fireside Chat At Cantor Global Healthcare Conference Sept. 28 at 8 a.m. EDT
Ocugen, Inc. (NASDAQ:OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced
Benzinga · 16h ago
Ocugen, Inc. to Participate in Fireside Chat at the Cantor Virtual Global Healthcare Conference
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that its Chairman, CEO, and Co-Founder, D...
GlobeNewswire · 16h ago
Novavax Stock Will Reward the Very Patient in the Long Term
Investor Place · 2d ago
Ocugen's India-Based Partner Concludes COVID-19 Vaccine Trials In Children: Report
Benzinga · 3d ago
Bharat Biotech has Completed Phase 2 and 3 Clinical Trials of Covaxin for Use in Children 2 to 18 Years; Chairman Krishna Ella said Covaxin Production would Reach 55M Doses in October vs 35M in September
Live Mint https://www.livemint.com/news/india/bharat-biotech-completes-covaxin-phase-2-3-clinical-trials-for-children-11632213730051.html
Live Mint · 3d ago
Top Biotech Stocks for Q4 2021
The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. ...
Investopedia · 3d ago
Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19...
GlobeNewswire · 6d ago
Insider Sell: Ocugen
MT Newswires · 6d ago
Ocugen Partner 'Bharat Biotech awaits feedback from WHO for Covaxin emergency use' -India's Business Standard
https://www.business-standard.com/article/international/bharat-biotech-awaits-feedback-from-who-for-covaxin-emergency-use-121091700551_1.html
Benzinga · 09/17 10:52
I’d Take Nio Stock’s 12-Month Double Despite Falling Below $50
Investor Place · 09/17 10:00
BRIEF-Ocugen Inc Provided An Update With Respect To Impact Of Co’S Regulatory Submission To Health Canada For Covaxin
reuters.com · 09/15 21:40
10 Cheap Small-Cap Stocks to Buy
In this article, we discuss the 10 cheap small-cap stocks to buy. You can skip our detailed analysis of the cheap small-cap stocks and go directly to read the 5 Cheap Small-Cap Stocks to Buy. As the global stock market is on its way to a remarkable recover...
Insider Monkey · 09/15 16:33
Do Options Traders Know Something About Ocugen (OCGN) Stock We Don't?
Investors need to pay close attention to Ocugen (OCGN) stock based on the movements in the options market lately.
Zacks · 09/15 12:34
72 Biggest Movers From Yesterday
Gainers
Benzinga · 09/14 08:50
Where's Ocugen Stock Headed Monday And Why?
Ocugen Inc. (NASDAQ: OCGN) shares were trading higher Monday, after Bharat Biotech: a company partner, was given the nod for a COVID-19 vaccine by the World Health Organization. The company saw a large upward movement Monday morning. Ocugen is trading up 1...
Benzinga · 09/13 19:05
Why Are Ocugen Shares Surging On Monday?
According to sources, the World Health Organization (WHO) is likely to grant India's COVID-19 vaccine, Covaxin, for an emergency use listing (EUL) this week. Ocugen Inc (NASDAQ: OCGN) is the U.S. partner for the vaccine.
Benzinga · 09/13 17:04
WHO Gives Nod To Bharat Biotech's COVID-19 Vaccine; Covaxin Expected This Week. BZ NOTE: Ocugen Is A Partner With Bharat Biotech On COVID-19 Vaccine
-Reuters
Reuters · 09/13 14:18
Vaxart Stock Is One Vaccine Also-Ran Worth Another Look
Investor Place · 09/08 10:00
U.S. inoculates 75% of adults with at least one dose of COVID-19 vaccine
According to the White House, three-quarters of adults in the U.S. have received at least one dose of a COVID-19 vaccine as of Tuesday - Bloomberg. White House COVID-19 data
Seekingalpha · 09/08 09:23
Ocugen, Inc. to Present at Upcoming Citi and H.C. Wainwright Investment Conferences
MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today an...
GlobeNewswire · 09/07 21:22
Webull provides a variety of real-time OCGN stock news. You can receive the latest news about Ocugen Inc through multiple platforms. This information may help you make smarter investment decisions.
About OCGN
Ocugen, Inc. is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing vaccine for COVID-19. The Company's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. COVID-19 Vaccine is developing, manufacturing and commercializing COVAXIN for the prevention of COVID-19 in humans in the Ocugen Covaxin Territory. COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus. The Modifier Gene Therapy platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). It is developing OCU200, a novel biologic product candidate to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet AMD. OCU400, its first product candidate being developed with its modifier gene therapy platform.